OPEN END-TURBO-OPTIONSSCHEIN - NOVAVAX Stock

Certificat

DE000HG4FTE7

Market Closed - BOERSE MUENCHEN 03:36:48 2024-05-10 pm EDT
5.91 EUR -6.64% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - NOVAVAX
Current month-7.51%
1 month-7.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
24-05-10 5.91 -6.64% 0
24-05-09 6.33 -0.16% 0
24-05-08 6.34 +0.16% 0
24-05-07 6.33 +0.48% 0
24-05-06 6.3 +0.16% 0

Real-time BOERSE MUENCHEN

Last update May 10, 2024 at 03:36 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying NOVAVAX, INC.
Issuer HSBC
WKN HG4FTE
ISINDE000HG4FTE7
Date issued 2022-07-14
Strike 72.39 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.46
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 6.47
Lowest since issue 0.93

Company Profile

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Sector
-
More about the company

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Novavax, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.88 USD
Average target price
19.75 USD
Spread / Average Target
+122.41%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW